Viridian Therapeutics, Inc. (VRDN) News
Track canonical SquawkNews coverage tagged to VRDN, Viridian Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Sling Therapeutics raises $123 million for thyroid eye disease late-stage trial
Sling Therapeutics said it raised $123 million to advance a late-stage trial of its experimental oral drug for thyroid eye disease.
EQUITY | Sep 16, 2026, 11:00 AM UTC
L
VRDN highlights Lumvoa IV launch strength and TED pipeline progress
TradingView News says Lumvoa IV’s launch is seeing strong early engagement and demand, alongside pipeline advancement for expanding in chronic TED. It also cites a Q1 2027 sub-Q BLA submission and FcRn/TSHR program progr
EQUITY | Sep 08, 2026, 06:27 PM UTC
L
VRDN Lumvoa IV launch draws prescriber engagement and robust demand
VRDN says its Lumvoa IV launch is seeing broad prescriber engagement and robust demand, supported by streamlined patient access and payer strategies. The company also points to pipeline progress including a sub-Q BLA sub
EQUITY | Sep 08, 2026, 05:55 PM UTC
L
Viridian Metals closes non-brokered private placement and market making deal
Viridian Metals Inc. says it has closed its previously announced non-brokered private placement of units, further to an Aug. 24, 2026 release. The closing also follows a market making agreement with an independent tradin
EQUITY | Sep 04, 2026, 10:27 PM UTC
L
Viridian Therapeutics to participate in Wells Fargo healthcare conference fireside chat
Viridian Therapeutics (Nasdaq: VRDN) says senior management will take part in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference.
EQUITY | Sep 02, 2026, 08:00 PM UTC
L
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ: VRDN ) with a Outperform and raises the price target from $34 to $35.
EQUITY | Jun 30, 2026, 03:34 PM UTC
L
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ: VRDN ) with a Buy and raises the price target from $35 to $38.
EQUITY | Jun 30, 2026, 01:58 PM UTC
L
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ: VRDN ) with a Outperform and raises the price target from $32 to $43.
EQUITY | Jun 30, 2026, 12:47 PM UTC
M
Wells Fargo Upgrades Viridian Therapeutics to Overweight, Raises Price Target to $31
Wells Fargo analyst Derek Archila upgrades Viridian Therapeutics (NASDAQ: VRDN ) from Equal-Weight to Overweight and raises the price target from $20 to $31.
EQUITY | Jun 29, 2026, 04:53 PM UTC
H
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket
Shares of Universe Pharmaceuticals Inc (NASDAQ: UPC ) rose sharply in pre-market trading after the company announced it will acquire Best Praise International for $10.75 million. Universe Pharmaceuticals shares jumped 22
RATES | Jun 29, 2026, 11:03 AM UTC
M
Needham Reiterates Buy on Viridian Therapeutics, Maintains $32 Price Target
Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ: VRDN ) with a Buy and maintains $32 price target.
EQUITY | Jun 29, 2026, 10:40 AM UTC
H
Stock Market Today: Dow Jones, S&P 500 Futures Gain As Trump Admin Says US, Iran Will 'Stand Down'—Verizon, HP, Universe Pharmaceuticals In
U.S. stock futures rose on Monday, as the Dow Jones, Nasdaq 100, and S&P 500 indices rose, following Friday’s mixed close. Late Sunday, the Donald Trump administration announced that both the U.S. and Iran will " stand d
MACRO | Jun 29, 2026, 09:11 AM UTC
H
Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Concentrix Corp. (NASDAQ: CNXC ) to post quarterly earnings at $2.6
EARNINGS | Jun 29, 2026, 06:34 AM UTC
H
VRDN: FDA Approves Lumvoa
Viridian Therapeutics receives FDA approval for Lumvoa to treat thyroid eye disease and plans to launch immediately
EQUITY | Jun 26, 2026, 10:03 PM UTC